For the quarter ending 2025-09-30, CORT had $22,393K increase in cash & cash equivalents over the period. $54,481K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 19,668 | 55,696 |
| Stock-based compensation | 22,879 | 40,853 |
| Accretion of marketable securities | -1,005 | -3,005 |
| Depreciation and amortization | 289 | 571 |
| Deferred income taxes | 9,114 | -31,469 |
| Non-cash amortization of right-of-use asset | 188 | 360 |
| Trade receivables | 5,062 | 10,591 |
| Insurance recovery receivable related to melucci litigation | 0 | 0 |
| Inventory | 3,943 | 4,021 |
| Prepaid expenses and other current assets | 13,461 | 2,232 |
| Other assets | -254 | 1,693 |
| Accounts payable | 10,921 | 8,149 |
| Accrued research and development expenses | -727 | -4,819 |
| Accrued and other liabilities | 17,158 | 6 |
| Accrued settlement related to melucci litigation | 0 | 0 |
| Long-term accrued income taxes | -1,545 | 1,593 |
| Operating lease liability | -247 | -331 |
| Net cash provided by operating activities | 54,481 | 49,067 |
| Purchases of property and equipment | 0 | 161 |
| Proceeds from sales and maturities of marketable securities | 52,000 | 205,536 |
| Purchases of marketable securities | 37,355 | 138,419 |
| Net cash provided by (used in) investing activities | 14,645 | 66,956 |
| Proceeds from stock option exercises, net of issuance costs | 2,033 | 10,975 |
| Proceeds from purchases under the employee stock purchase program | 2,170 | 4,990 |
| Repurchases of common stock in connection with stock repurchase program | 42,464 | 130,451 |
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | 8,152 | 28,251 |
| Net cash used in financing activities | -46,413 | -142,737 |
| Net effect of exchange rate changes on cash and cash equivalents | -320 | 1,794 |
| Net (decrease) increase in cash and cash equivalents | 22,393 | -24,920 |
| Cash and cash equivalents at beginning of period | 127,665 | - |
| Cash and cash equivalents at end of period | 125,138 | - |
CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT)